1,2,3-Trimethyl-piperidin | 38596-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1,2,3-Trimethyl-piperidin
• 英文别名: 1,2,3-trimethyl-piperidine；1,2,3-Trimethylpiperidine
• CAS: 38596-93-9
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: ZURNMVFCRRBOGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,2,3-Trimethyl-piperidin 在 mercury(II) diacetate 、 溶剂黄146 作用下， 生成 1,5,6-trimethyl-1,2,3,4-tetrahydro-pyridine
  参考文献：
  名称：

  Unsaturated Amines. X. The Mercuric Acetate Route to Substituted Piperidines, Δ²-Tetrahydropyridines and Δ²-Tetrahydroanabasines

  摘要：

  DOI：

  10.1021/ja01576a056
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 铂 作用下， 生成 1,2,3-Trimethyl-piperidin
  参考文献：
  名称：

  Unsaturated Amines. X. The Mercuric Acetate Route to Substituted Piperidines, Δ²-Tetrahydropyridines and Δ²-Tetrahydroanabasines

  摘要：

  DOI：

  10.1021/ja01576a056

文献信息

• Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
  申请人：Lead Discovery Center GmbH

  公开号：EP2634189A1

  公开（公告）日：2013-09-04

  The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

  本发明涉及吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用盐，这些衍生物作为药用活性剂的应用，特别是用于预防和/或治疗传染病，包括机会性感染病、免疫性疾病、自身免疫疾病、心血管疾病、细胞增殖性疾病、炎症、勃起功能障碍和中风，以及含有至少一种所述吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用盐的药物组合物。此外，本发明涉及所述吡唑并[1,5-a][1,3,5]三嗪衍生物作为蛋白激酶抑制剂的应用。
• Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
  申请人：Lead Discovery Center GmbH

  公开号：EP2634190A1

  公开（公告）日：2013-09-04

  The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

  本发明涉及吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用可接受盐，以及这些衍生物作为药用活性剂的用途，特别是用于预防和/或治疗传染病，包括机会性疾病、免疫疾病、自身免疫疾病、心血管疾病、细胞增殖性疾病、炎症、勃起功能障碍和中风，以及含有至少一种所述吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用可接受盐的药物组合物。此外，本发明涉及将所述吡唑并[1,5-a][1,3,5]三嗪衍生物用作蛋白激酶的抑制剂。
• [EN] COMPOUNDS AS GLP-1R AGONISTS<br/>[FR] COMPOSÉS EN TANT QU'AGONISTES DE GLP-1R
  申请人：TERNS PHARMACEUTICALS INC

  公开号：WO2022040600A1

  公开（公告）日：2022-02-24

  The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Also provided are pharmaceutical compositions containing such compounds, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Methods of prepare these compounds and compositions and method of using them to treat or present a disease or a condition mediated by GLP-1R.

  本申请提供了可用作胰高血糖素样肽-1受体（GLP-1R）激动剂的化合物，或者是这些化合物的立体异构体、互变异构体，或者是任何这些化合物的药用可接受盐。还提供了含有这些化合物、或者这些化合物的立体异构体、互变异构体，或者这些化合物的药用可接受盐的药物组合物。制备这些化合物和组合物的方法，以及使用它们来治疗或预防由GLP-1R介导的疾病或状况的方法。
• Phenylpiperidine derivatives as melanocortin-4 receptor modulators
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP1842846A1

  公开（公告）日：2007-10-10

  The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及取代苯基哌啶衍生物作为黑色素皮质素-4受体调节剂。根据结构和立体化学，本发明的化合物要么是人类黑色素皮质素-4受体（MC-4R）的选择性激动剂，要么是选择性拮抗剂。激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。一般来说，涉及MC-4R调节的所有疾病和疾病都可以用本发明的化合物进行治疗。
• [EN] HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION
  申请人：FOCHON PHARMACEUTICALS LTD

  公开号：WO2020253659A1

  公开（公告）日：2020-12-24

  Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

  提供了某些URAT1抑制剂，其制药组合物以及使用方法。